88 Energy (EEENF) Stock Moves Closer To 2 cents: How To Trade Now?
Back in April the stock of the oil and natural gas company 88 Energy Limited (OTCMKTS:EEENF) had displayed considerable volatility owing to certain developments. However, over the course of the past few weeks the stock has been in the middle of a phase of consolidation.
When that happens, then there is a possibility of the stock breaking out and hence, it might be a good idea for investors to take a closer look at the 88 Energy stock. The 88 Energy came into focus in March this year, when it soared to 20 cents a share, however, an update from the company back in April rocked and sent the shares tumbling.
In April, the company announced that equipment failure had led to a power outage at two of its highest prospect zone. It disrupted the sampling work at those two properties that are part of 88 Energy’s Alaskan Peregrine project.
That proved to be a major blow for the stock as a major selloff ensured amidst panic from customers and the stock crashed. However, the stock recovered some days later on April 27 after the company provided another operational update in relation to its drilling activities in Alaska.
88 Energy announced that it started the testing on the sidewell cores, fluid samples, mud gas and cuttings at the property in question. At the time, the company revealed that the results from the testing are going to be revealed in 10 weeks.
It goes without saying that many investors are going to be eagerly waiting for the results from the tests and it remains to be seen if the publication leads to any rally or not. That might actually be one of the major reasons why the stock is currently trading flat. Once the results are declared, there might be considerable movement in the stock either way depending on the nature of the findings.
Zomedica (ZOM) Stock May Get Attention After The Recent Sell-Off
Over the course of the year so far, the Zomedica (NYSEAMERICAN:ZOM) stock has had a rollercoaster run so far this year. At this point, the stock is trading at less than $1 a share and investors might be interested in seeing if the stock can go past that level again.
In this situation, it might be necessary for investors to take a closer look at the company and its business. The company currently boasts of one major product, the Truforma diagnostic platform for cats and dogs, which was launched in March this year. Experts believe that Zomedica, like many other penny stocks remains a speculative play; however, there are certain compelling arguments to be made regarding the stock.
It was not too long ago that the Zomedica stock was trading at $2 a share and before it can retrace its way to those levels, the company perhaps needs to ensure that it continues to grow its sales. It is sometimes possible for companies to grow if they can concentrate wholeheartedly on one thing and in case of Zomedica it is its sales.
It goes without saying that such a strategy can and often does lead to losses. However, at the same time the company is going to get the advantages that come with economies of scale.
When that happens, Zomedica will then be able to come up with other diagnostic products which will go a long way in building an entirely new ecosystem and eventually turn the company into a major player in the animal healthcare industry.
That will then turn the company from depending on the sales of its solitary product; Truforma and help in bringing about long-term growth. Zomedica has already started working on boosting its sales in a big way and recently decided to speed up the establishment of a direct sales model. These are important factors that could help the company in generating meaningful growth in the long term.
Sunshine Biopharma (SBFM) Stock Moves Toward New Highs: What’s The Plan?
There were many stocks that rallied on Tuesday but the gains in the Sunshine Biopharma (OTCMKTS:SBFM) stock was particularly notable. After the company made an announcement yesterday with regards to the working mechanisms of its anticancer product Adva-27a, the stock came into sharp focus.
As investors piled on to the Sunshine stock, it rallied strongly and ended up clocking gains of as much as 142%. The findings put forward by the company in relation to the treatment were compelling as well. Sunshine stated that Adva-27a displayed two primary activities. One was that it could evade P-glycoprotein and the other was that the treatment could inhibit Topoisomerase II.
The fact that the treatment can evade P-glycoprotein is perhaps the most important finding. It is a form of protein that is found in around 50% of all types of cancers and is responsible for resistance to treatment. There are a large number of cancer medicines that have been rendered ineffective by P-glycoprotein.
In addition to that, it is necessary to note that experts agree that resistance to a multi medicine treatment due to presence of P-glycoprotein has been regarded as one of the biggest reasons behind the failure of cancer treatments.
This feature gives Adva-27a a distinct potential competitive advantage over many of the other products in the market and hence, the rally in the stock was perhaps not such a surprise. The Chief Executive Officer of the company, Dr. Steve Silaty, spoke about the findings as well.
He said that the findings and their implications could have a considerable impact on the direction of therapies for cancer as a whole. He went on to state that the company is quite excited about the fact that Sunshine is soon going to roll out a new medicine that could have a meaningful impact on patients suffering from cancer all over the world.
Asia Broadband (AABB) Stock Jumps Again: Up 40% in a Week
The crypto sector may have had a pretty shocking time over the past week but companies there are some companies in the sector that did not do too badly in terms of stock performance.
One of those is Asia Broadband Inc (OTCMKTS:AABB). On Monday the stock was on the move and rallied by as much as 12% to take its gains for the past week to 40%. Asia Broadband’s core business is related to the precious metals like gold but the company has made a massive effort to get into the fast growing cryptocurrency space in a big way. The company is now working on its own cryptocurrency exchange after having recently launched its own cryptocurrency.
In this regard, it is important to point out that back in March, the company had launched its own cryptocurrency token named the AABBG token. However, it is also necessary to point out that the AABBG tokens are backed by physical gold belonging to Asia Broadband worth as much as $30 million.
Recently, the company reported that it has made considerable progress in relation to the development of its cryptocurrency platform and that could actually prove to be a major boost for its crypto token as well.
Those who actually purchase the AABBG token are going to have two kinds of advantages. One of those is that it is going to be a pretty stable digital asset considering the fact that each token is backed by 0.1 gram of spot price gold.
On the other hand, the token could also appreciate at price like other cryptocurrencies and thereby give its holders a profit. However, if price appreciation is to happen then the AABBG token also needs to be in circulation in exchanges and that can only happen once the Asia Broadband crypto exchange is in place. The current optimism about the Asia Broadband stock is understandable and investors could consider keeping it in their watch lists at this point.
Is HUMBL (HMBL) Stock About To Recover After The Recent News?
At the turn of the year, the HUMBL Inc (OTCMKTS:HMBL) stock was one of the biggest gainers among penny stocks but it has corrected quite sharply in recent times. However, on Monday, the HUMBL stock moved sharply and ended up making gains of 9.5%.
Could it be the start of another uptrend in the stock? The latest gains made by the stock were triggered by an announcement from the company yesterday. In recent times Non-Fungible Tokens (NFTs) have become hugely popular and HUMBL announced the launch of its own NFT named Gallery yesterday. It is a significant new step from the company and one which sparked optimism among investors too.
The NFTs will be made available to interested customers on the website HUMBLpay.com. The gallery is going to allow content developers to create their own NFTs to protect their interests and consumers will be able to purchase them from the website.
While it is true that HUMBL has been primarily involved with mobile payments, the company has also created a digital assets platform which is meant for blockchain based tokenization. The tokenization is aimed at real world use cases like ticketing, financial services, payments and NFTs among others.
The new NFT is going to be entirely focussed on artists, content creators and assorted entertainers across a range of fields like fashion, gaming, sports, photography and music among others. The first HUMBL NFT Gallery is going to be made up of a collection of photographs from Jared Raskind and Andrew Small.
Both photographers have been in the business for a long time and over the course of the past decade, the duo has developed collections that are meant for private groups as well as the larger public. It goes without saying that it is an important step for HUMBL and could bring about considerable revenues in the long term.
Healthier Choices Management (HCMC) Stock May Trade Sideways in Absence of Major Catalyst
The Healthier Choices Management (OTCMKTS:HCMC) stock has been on the radars of plenty of investors for quite a while. This past Friday the stock experienced a bit of volatility, although the trading volumes were quite high. The Healthier Choices Management stock was in heavy action on Friday and as many as a billion shares in the company were traded during the course of the trading day.
For perspective, investors need to note that the average daily trading volume of the Healthier Choices Management stock stands at only 267 million shares. In recent times, the stock has soared from triple zero levels to double zero ones and that has been another factor behind increased interest.
At this point, Healthier Choices Management has as many as 300 billion shares outstanding but the frenzy around the stock on Friday was triggered by the company’s rights offering. Last week the company had also announced that that it was going to issue a subscription period in relation to that offering.
On Friday, most of the investors who already hold the Healthier Choices Management stock noticed a “422rgt019”pop up in their trading accounts. Initially there was a lot of speculation about the significance of the pop up.
Many believed it might have been related to reverse stock split or a dividend payout. Amidst frenzied speculation, the trading volume in the stock soared to new heights. However, it was later pointed out by other investors that the pop up was related to the announcement made by the company in relation to the rights offering earlier on in the week.
As per the provisions of the rights offering, existing investors in Healthier Choices Management are going to be awarded a solitary right for each block of four shares that they hold. Investors will have the right to pick up shares in the company at a future date.
HIVE Blockchain (HVBTF) Stock is Down 60% From The Peak: But Why?
The collapse in the cryptocurrency space over the course of the past few days has been quite dramatic and it has also brought considerable pressure on the stocks of companies that are engaged in that sector. One such company is HIVE Blockchain (OTCMKTS:HVBTF), which saw its stock come under considerable trading pressure due to the fall in Bitcoin last week.
At this point, the HIVE stock has declined by as much as 60% since hitting its highest levels in 52 weeks in February this year. The stock soared from only 9 cents a share back in January this year to a high of $5.75 a share in February.
In this regard, it is important to note that just like the cryptocurrency sector at large, the HIVE stock also suffers from spells of extreme volatility and it is important for investors to be cautious when dealing with this stock.
Considering the sort of gains it generated earlier this year, it might be worthwhile for investors to keep track of the HIVE Blockchain stock at this point. Moreover, the possibilities of a rebound in the crypto sector could also act as a positive catalyst for a strong rebound for the HIVE stock.
One of the important factors to keep in mind regarding HIVE Blockchain is that the company is committed to clean and responsible cryptocurrency mining operations. At a time when Bitcoin collapsed due to Elon Musk’s tweet with regards to the environmental implications of the world’s biggest cryptocurrency, this is a highly important factor to future success.
The company’s mining activities are run in colder climates since it is not only efficient with regards to costs but also power. Cryptocurrency mining has been criticized for using high amounts of energy and HIVE’s responsible mining operations could make it stand out in a highly competitive industry. It could be a good idea for investors to include the HIVE stock in their watch lists.
Atossa Therapeutics (ATOS) Stock Consolidates After The Big Jump: A Buy?
Investors are frequently on the lookout for stocks that have performed well over a period of several weeks and that is understandable considering the need to observe trends over a certain period.
By that token, it could be a good move for investors to consider the Atossa Therapeutics (NASDAQ:ATOS) stock, which has managed to deliver gains of as much as 120% over the course of the past month. It is a clinical stage biopharmaceutical firm and is currently engaged in developing new age medicines that are meant for cancers and for infectious diseases. At this point in time, Atossa is concentrating on medicines related to COVID 19 and breast cancer.
Last week, the company announced its financial results for the first fiscal quarter that ended on March 31, 2021 and also provided key updates with regards to its operations. The company did not report any source of sustainable revenues in the first quarter but at the same time investors need to note that Atossa did not record any cost of revenues either. On the other hand, Atossa reported cash, restricted cash and cash equivalents to the tune of $137.7 million in the quarter.
While it may be true that there was no cost of revenues in the quarter, the company’s total operating expenses did rise. In the first quarter, the total operating expenses stood at $3531000, while in the prior year period Atossa spent $2937000. That reflects a rise of around 20%. In this regard, it might be a better move from investors to possibly take a look at the expenses towards research and development activities.
The research and development expenses for the quarter came in at $1,379,000 and reflects a considerable rise from the $939,000 that was recorded in the prior-year period. In light of the recent gains and the company’s continued efforts, it might be a good move to keep Atossa in the watch lists.